Close Menu

This story has been updated with additional details on the FDA approved companion test for Alunbrig and about how patients were genetically tested in the ALTA 1L study. 

NEW YORK – The US Food and Drug Administration on Friday approved Takeda Pharmaceutical's brigatinib (Alunbrig) as a treatment for ALK-positive, metastatic non-small cell lung cancer.

The agency simultaneoulsy approved Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit to identify patients with ALK rearrangements who are likely to benefit from brigatinib.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.